{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:02:57Z","timestamp":1762866177996},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ejmech.2013.03.056","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T06:17:11Z","timestamp":1365229031000},"page":"302-313","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb\/IIIa with highly overlapped pharmacophores"],"prefix":"10.1016","volume":"64","author":[{"given":"Uro\u0161","family":"Trstenjak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janez","family":"Ila\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijel","family":"Kikelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2013.03.056_bib1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2013.03.056_bib2","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00018-006-6219-z","article-title":"Direct thrombin inhibitors, a survey of recent developments","volume":"63","author":"Schwienhorst","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2013.03.056_bib3","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2174\/0929867043364540","article-title":"Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants","volume":"11","author":"Steinmetzer","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/13543784.15.8.843","article-title":"Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases","volume":"15","author":"Kubitza","year":"2006","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2013.03.056_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/13543776.16.2.119","article-title":"Progress in the discovery of factor Xa inhibitors","volume":"16","author":"Casimiro-Garcia","year":"2006","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2013.03.056_bib6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2174\/0929867043364568","article-title":"Inhibitors of tissue factor\/factor VIIa for anticoagulant therapy","volume":"11","author":"Lazarus","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib7","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.2174\/138161205774913282","article-title":"Recent advances in the discovery of tissue factor\/factor VIIa inhibitors and dual inhibitors of factor VIIa\/factor Xa","volume":"11","author":"Kranjc","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2013.03.056_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2174\/0929867043365314","article-title":"Peptidomimetics. Antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications","volume":"11","author":"Andronati","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib9","first-page":"672","article-title":"ACC\/AHA guidelines for the management of patients with valvular heart disease","volume":"7","author":"Bonow","year":"1998","journal-title":"J.\u00a0Heart Valve Dis."},{"key":"10.1016\/j.ejmech.2013.03.056_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/hrt.2005.077164","article-title":"Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion","volume":"92","author":"Yang","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ejmech.2013.03.056_bib11","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2013.03.056_bib13","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2174\/0929867043364432","article-title":"Dual inhibitors of the blood coagulation enzymes","volume":"11","author":"Kranjc","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib14","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.2174\/156802611798184364","article-title":"Multitarget antithrombotic drugs","volume":"11","author":"Ili\u0107","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib15","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1021\/jm8003448","article-title":"3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb\/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual action","volume":"51","author":"Ila\u0161","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1021\/jm048984g","article-title":"Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazine-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities","volume":"48","author":"\u0160tefani\u010d Anderluh","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2012.01.059","article-title":"Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold","volume":"50","author":"Ili\u0107","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejmech.2013.01.002","article-title":"Towards dual antithrombotic compounds \u2013 balancing thrombin inhibitory and\u00a0fibrinogen GPIIb\/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism","volume":"62","author":"Ili\u0107","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.181321","article-title":"The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor\/glycoprotein IIbIIIa antagonist, exceeds that of the\u00a0coadministered parent compounds","volume":"338","author":"Hechler","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2013.03.056_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2013.03.056_bib21","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2174\/1381612033453901","article-title":"Recent advances in the discovery and development of direct coagulation factor Xa inhibitors","volume":"9","author":"Gould","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2013.03.056_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-006-5579-4","article-title":"New anticoagulants: anti IIa vs anti Xa\u2013is one better?","volume":"21","author":"Bauer","year":"2006","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2013.03.056_bib23","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature02976","article-title":"Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics","author":"Xiao","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2013.03.056_bib25","unstructured":"U. Trstenjak, J. Ila\u0161, D. Kikelj, Dual inhibitor of factor Xa and thrombin made by modification of the morpholin-3-one moiety in rivaroxaban, unpublished results."},{"key":"10.1016\/j.ejmech.2013.03.056_bib26","unstructured":"The synthesis of corresponding (R)-isomer was not successful."},{"key":"10.1016\/j.ejmech.2013.03.056_bib27","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0960-894X(03)00130-6","article-title":"Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an izoxazoline library","volume":"13","author":"Lam","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2013.03.056_bib28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2013.03.056_bib29","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2013.03.056_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0167-4838(83)90272-8","article-title":"The action of thrombin on peptide p-nitroanilide substrates. Substrate selectivity and examination of hydrolysis under different reaction conditions","volume":"742","author":"Lottenberg","year":"1983","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2013.03.056_bib31","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/1439-7633(20021104)3:11<1078::AID-CBIC1078>3.0.CO;2-2","article-title":"Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues","volume":"3","author":"Addicks","year":"2002","journal-title":"ChemBioChem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341300216X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341300216X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:01:03Z","timestamp":1539734463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341300216X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":31,"alternative-id":["S022352341300216X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.03.056","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb\/IIIa with highly overlapped pharmacophores","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2013.03.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}